Table 3 Univariate and multivariate analyses for OS in cohorts A and B combined
From: Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
Cohort A | Cohort B | |||||||
|---|---|---|---|---|---|---|---|---|
Factors | Univariate analysis HR (95% C.I.) | p | Multivariate analysis HR (95% C.I.) | p | Univariate analysis HR (95% C.I.) | p | Multivariate analysis HR (95% C.I.) | p |
Age (≥ 65 vs ≤ 65) | 0.9 (0.80–1.04) | 0.18 | – | – | 1.13 (0.86–1.47) | 0.38 | – | – |
Gender | ||||||||
(male vs female) | 1.03 (0.89–1.18) | 0.73 | – | – | 1.20 (0.87–1.67) | 0.27 | – | – |
ECOG PS | ||||||||
1 vs 0 | 1.59 (1.37–1.83) | < 0.0001 | 1.45 (1.24–1.69) | < 0.0001 | 1.59 (1.20–2.11) | 0.001 | 1.51 (1.14–2.00) | 0.04 |
2 vs 0 | 3.47 (2.71–4.45) | < 0.0001 | 3.09 (2.38–4.02) | < 0.0001 | 2.53 (1.54–4.17) | < 0.0001 | 2.46 (1.49–4.05) | < 0.0001 |
Smoking habits | ||||||||
Current/former vs never | 0.85 (0.72–1.00) | 0.05 | – | – | 1.27 (0.79–2.07) | 0.32 | – | – |
Brain mets (yes vs no) | 1.24 (1.06–1.43) | 0.006 | – | – | 1.07 (0.70–1.63) | 0.75 | – | – |
Liver mets (yes vs no) | 1.84 (1.58–2.15) | < 0.0001 | 1.64 (1.39–1.93) | < 0.0001 | 1.58 (1.16–2.15) | 0.004 | 1.43 (1.01–1.95) | 0.03 |
Bone mets (yes vs no) | 1.67 (1.46–1.91) | < 0.0001 | 1.50 (1.30–1.73) | < 0.0001 | 1.90 (1.47–2.47) | < 0.0001 | 1.78 (1.37–2.31) | < 0.0001 |
Previous CT Lines | ||||||||
2 vs 1 | 0.87 (0.73–1.03) | 0.10 | – | – | 0.91 (0.61–1.22) | 0.54 | – | – |
> 2 vs 1 | 1.03 (0.88–1.21 | 0.67 | 0.73 (0.53–1.02) | 0.06 | ||||